01731nas a2200325   4500000000100000008004100001260001700042653001000059653003000069653001000099653002100109653001100130653001100141653002900152653002800181653000900209653002200218100001500240700001500255700001700270700001500287700001200302700001200314700001200326245009800338300001000436490000700446520093800453022001401391       1992                            d  c1992 May-Jun10aAdult10aAntimony Sodium Gluconate10aChild10aChild, Preschool10aFemale10aHumans10aLeishmaniasis, Cutaneous10aLeishmaniasis, Visceral10aMale10aTreatment Outcome1 aHassan A M1 aGhalib H W1 aZijlstra E E1 aEltoum I A1 aSatti M1 aAli M S1 aAli H M00aPost kala-azar dermal leishmaniasis in the Sudan: clinical features, pathology and treatment.  a245-80 v863 a<p>The clinical features, pathology, immune responses, diagnosis and treatment of post kala-azar dermal leishmaniasis (PKDL) in the Sudan are described and discussed. The disease is characterized by maculopapular or nodular lesions on the face, limbs or trunk. Lesions appear during or within months after the treatment of visceral leishmaniasis, but in 2 of 19 patients there was no previous history of kala-azar. PKDL may be confused with leprosy both clinically and pathologically. Similarities and differences between the 2 diseases are discussed. Unlike visceral leishmaniasis, the peripheral lymphoid cells of patients with PKDL respond to Leishmania antigen and some are leishmanin positive. The response to intravenous sodium stibogluconate (20 mg/kg for 30 d) was reasonably good but some patients required repeated or more prolonged treatment. Ketoconazole in a dose of 10 mg/kg daily for 4 weeks had no effect on PKDL.</p>  a0035-9203